A condition that affects up to 80% of adolescents and 40% of adults rarely receives a mechanistic explanation. Here is what is actually happening beneath the skin, why most remedies fail to address it, and what changes when the formulation matches the mechanism.
The answer in one paragraph
Keratosis pilaris is a chronic disorder of follicular keratinisation, in which keratin, a structural protein produced by the body's skin cells, accumulates abnormally around the opening of the hair follicle and forms a microscopic plug. The plug traps the hair beneath it and produces the raised papule, the textured surface, and the persistent roughness that defines the condition. Because the disorder is structural and occurs beneath the surface, treatments that operate only on the surface, including most moisturisers, scrubs, and oils, do not resolve it. Mechanistic resolution requires a keratolytic active, applied consistently, at a concentration and pH sufficient to dissolve the keratin compaction itself.
What keratosis pilaris is, biologically
The medical name for keratosis pilaris is follicular hyperkeratosis. Translated, this means "excess keratin formation around the hair follicle." Each affected follicle behaves identically. The cells that line the follicular opening, which are continuously produced and shed in healthy skin, fail to shed at the normal rate. They compact instead.
The result is a microscopic plug of keratinised cells obstructing the follicle. The hair beneath the plug grows but cannot emerge cleanly; it curls back beneath the surface or pushes upward against the obstruction. The skin around the plug responds with low-grade inflammation, which produces the characteristic redness seen in many cases, particularly the variant known as keratosis pilaris rubra.
Multiplied across thousands of follicles on the upper arms, thighs, and buttocks, the result is the stippled, gooseflesh texture that affects up to 80% of adolescents and 40% of adults, according to a 2025 literature review published in Cureus.
Why the condition persists into adulthood
Keratosis pilaris is genetically influenced. The tendency for follicular keratinisation to misfire is inherited, often within families, and frequently runs alongside related conditions including atopic dermatitis, ichthyosis vulgaris, and generalised xerosis. The 2025 Journal of Current Clinical Care review notes that KP typically appears in the first decade of life, worsens around puberty, and gradually improves with age. "Improves" is the operative word. It does not resolve.
For approximately 40% of adults, the genetic predisposition persists. The follicles continue to compact keratin abnormally for life. This is why the condition cannot be cured in the sense of permanent biological resolution. It can, however, be reliably managed. The question is not whether intervention is possible but which class of intervention reaches the level at which the disorder operates.
Why most treatments fail
The dominant approaches to KP in consumer skincare share a common flaw: they operate on the surface of skin rather than within the follicular structure where the keratin compaction sits.
- Moisturisers address the surface dryness that often accompanies KP, but they do not dissolve the keratin plug. They make the skin feel softer without changing the underlying texture. The bumps remain.
- Mechanical scrubs abrade the surface but cannot penetrate to the depth at which the obstruction occurs. They frequently worsen the surrounding inflammation, particularly in the rubra variant, by inflaming follicles that are already reactive.
- Oils sit on the stratum corneum as occlusive layers. They neither chemically dissolve keratin nor regulate the corneocyte turnover rate that drives the compaction in the first place.
- Physical extraction, including picking or squeezing, ruptures the follicle and reliably produces post-inflammatory hyperpigmentation and scarring, while doing nothing to address the underlying tendency to re-form plugs.
The 2025 Cureus review concluded that topical keratolytic agents, specifically alpha-hydroxy acids and urea, demonstrate the most consistent evidence of effectiveness across the clinical literature. The reason is mechanistic: keratolytics chemically dissolve the bonds holding compacted keratin in place, allowing the follicle to clear and resume normal function.
What actually works at the mechanistic level
Two categories of active address keratosis pilaris at the depth at which the disorder occurs.
The first is the alpha-hydroxy acid family, of which glycolic acid is the smallest molecule (76 daltons) and therefore the most penetrative for body skin. Glycolic acid works by dissolving the desmosomal bonds that hold corneocytes together. When applied consistently at a clinical concentration and the correct formulation pH, it accelerates the natural shedding cycle and prevents the compaction that drives KP from forming.
The second is urea, which functions both as a humectant at lower concentrations and as a keratolytic at higher ones. Above 10%, urea begins to chemically break down keratin compaction directly. It is one of the few actives that complements glycolic acid's mechanism rather than duplicating it, addressing the same target structure through a different chemical pathway.
Niacinamide, a third active commonly included in formulations engineered for KP, does not directly dissolve keratin but performs a structural role: it supports the skin barrier through the resurfacing cycle, reduces the post-inflammatory pigmentation that often accompanies long-term KP, and modulates the low-grade inflammation that contributes to the rubra variant.
Why concentration and pH determine outcomes
An alpha-hydroxy acid lotion that lists glycolic acid on the panel is not necessarily a clinical-strength keratolytic. Two formulation variables determine whether the active actually works at the depth required.
The first is concentration. Below 10%, glycolic acid functions more as a surface humectant than as a keratolytic. Visible reduction of KP papules requires concentrations of 10% or greater applied consistently to the affected areas. The dermatology benchmark for at-home, daily-use protocols sits at 10% to 12%.
The second is pH. Glycolic acid is biologically active only in its protonated form, which exists in significant proportion below pH 4.0. Above pH 4.0, the active fraction collapses, and the formulation behaves as a cosmetic moisturiser regardless of the percentage on the label. The therapeutic window for at-home glycolic body lotions is pH 3.6 to 4.0. Below 3.6, irritation potential rises sharply; above 4.0, clinical activity collapses.
A formulation that meets both thresholds, concentration and pH, supported by complementary actives and adequate barrier protection, is operating at the level at which keratosis pilaris exists. A formulation that meets only one is operating somewhere else.
The realistic timeline
Mechanistic change to keratosis pilaris is gradual and cumulative. The follicular structure does not reorganise in days. Published clinical observations suggest visible reduction in papule density and surface texture typically appears within 6 to 12 weeks of consistent application, three to four times weekly, of a clinical-strength keratolytic formulation. Some users see preliminary smoothness within 14 days; meaningful change in the underlying compaction takes the full cycle.
The condition will return if treatment is discontinued. This is not a failure of the treatment; it is a function of the genetics. The follicles will resume compacting keratin in the absence of an active that prevents them from doing so. Long-term management is the realistic frame. Cure is not.
What this means for product selection
If you are selecting a body lotion to address keratosis pilaris, the questions worth asking are mechanistic rather than aesthetic. A clinical-strength formulation will disclose its concentration, ideally disclose its pH, confirm that the active is buffered for tolerability, and include complementary actives such as urea and niacinamide for barrier support. Fragrance-free composition reduces the sensitiser load on skin that is already reactive in the rubra variant.
The 12% AHA Glycolic Acid Body Lotion is formulated to these specifications. The choice of 12% glycolic acid, buffered to pH 3.6 to 4.0, supported by urea and niacinamide, fragrance-free, reflects the formulation logic that the literature describes as the most consistently effective for KP. It is the formulation the framework points to, rather than a product the framework was reverse-engineered around.
Frequently asked questions
What causes keratosis pilaris?
Keratosis pilaris is caused by follicular hyperkeratosis: abnormal accumulation of keratin around the opening of the hair follicle, forming a microscopic plug. The tendency is genetically influenced and often runs in families. The condition typically appears in childhood, worsens around puberty, and improves but rarely resolves completely with age. It is not contagious, not infectious, and not caused by hygiene or diet.
Why does keratosis pilaris keep coming back?
Keratosis pilaris is a chronic genetic predisposition rather than a temporary condition. The follicles affected continue to compact keratin abnormally throughout life in approximately 40% of adults. When effective treatment is discontinued, the follicles resume their tendency. This is not a treatment failure; it is the underlying biology. Consistent long-term management is the realistic approach.
Why doesn't moisturiser fix keratosis pilaris?
Moisturisers operate on the surface of skin. Keratosis pilaris originates beneath the surface, within the follicular structure, where compacted keratin obstructs the follicle. A moisturiser can make the skin feel smoother by addressing accompanying dryness, but it does not dissolve the keratin plug. Resolution at the mechanistic level requires a keratolytic active, such as glycolic acid or urea, at a sufficient concentration and pH.
How long does it take for glycolic acid to work on keratosis pilaris?
Visible reduction in keratosis pilaris papules and surface texture typically appears within 6 to 12 weeks of consistent application, three to four times weekly, of a glycolic acid body lotion at 10% to 12% concentration and pH 3.6 to 4.0. Some users report preliminary smoothness within 14 days. Meaningful change to the underlying follicular compaction takes the full cycle of 6 to 12 weeks.
Does keratosis pilaris go away on its own?
Keratosis pilaris frequently improves with age but does not typically resolve completely. The condition appears in the first decade of life, worsens around puberty, and gradually diminishes through adulthood. However, approximately 40% of adults retain the condition. Active management with a clinical-strength keratolytic formulation produces consistent improvement that natural age-related fading does not.
References
- Dampa E, Patel R, Mishra S, et al. The Effectiveness of Topical Keratolytics (Alpha Hydroxy Acids, Beta Hydroxy Acids, Urea) in Treating Keratosis Pilaris: A Review of the Literature. Cureus. 2025;17(12):e100507. doi:10.7759/cureus.100507
- Maghfour J, Sivesind TE, Dellavalle RP, et al. Keratosis pilaris treatment paradigms: assessing effectiveness across modalities. Australasian Journal of Dermatology. Published online 2024. doi:10.1111/ajd.14271
- Suresh R, Bhargava P. Keratosis Pilaris: Epidemiology and Management. Journal of Current Clinical Care. 2025;15(1):15-19.
- Australasian College of Dermatologists. Keratosis pilaris: patient information. Sydney: ACD; 2024.
About The Lotion
The Lotion is an Australian clinical body skincare house formulating to the six-marker standard: at least 10% AHA concentration, buffered pH 3.6 to 4.0, supportive humectants, fragrance-free composition, no sensitiser load, and a vehicle calibrated for stratum corneum delivery. The brand publishes a single product: a 12% AHA Glycolic Acid Body Lotion with urea, niacinamide, and shea butter, formulated and manufactured in Australia.
The Lotion Editorial. Reviewed quarterly. Last updated May 2026.
